Multiple myeloma (MM) is a malignant clonal plasma cell disorder in the bone marrow and is
the second-most common hematologic malignancy in adults. Although patients with MM …

Background T-cell–redirecting therapies, such as bispecific antibodies and chimeric antigen
receptor T-cells, exploit the cytotoxic capabilities of the immune system to destroy cells …

Survival has improved in patients diagnosed with multiple myeloma (MM) over the last two
decades; however, there remains a paucity of data on the causes of death in MM patients …

In the MAIA study (median follow-up, 56.2 months), daratumumab plus lenalidomide and
dexamethasone (D-Rd) significantly improved progression-free survival (PFS) and overall …

Given the early use of triplet and quadruplet regimens, most patients with multiple myeloma
(MM) will be exposed and/or refractory to PIs, IMiDs, and anti-CD38 mAbs after first-or …

Multiple myeloma (MM) is an incurable plasma cell malignancy accounting for
approximately 10% of hematological malignancies. Identification of reliable biomarkers for …

Stem cell transplantation (SCT) has been an integral treatment modality for multiple
myeloma (MM) for decades. However, as standard‐of‐care therapies have improved, the …

Multiple myeloma (MM) is a plasma cell disorder that has recently experienced a dramatic
improvement in clinical outcomes mainly due to the advent of novel drugs and the …

Background: Multiple myeloma (MM) is an incurable plasma cell malignancy. Several
studies have demonstrated usefulness of the proteomic approach to identify potential …

Results Age of enrolled patients (median, range unless otherwise specified) 73 (IQR 71–76)
72 (55–80) 72 (65–80)